A new clinical trial is underway to test ibudilast, an asthma drug approved in Japan, for the treatment of severe COVID-19. Ibudilast is a MIF inhibitor. MIF is a gene that regulates immune response and is a driver of inflammation which results in the cytokine storm associated with coronavirus.
from Neuroscience News https://ift.tt/350tCEE
from Neuroscience News https://ift.tt/350tCEE
Comments
Post a Comment